A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors
- Conditions
- Neutropenia
- Registration Number
- NCT03798665
- Lead Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Brief Summary
Prospective, multicenter, non-interventional registration studies were used in this project . Eight hundreds patients with solid tumors who met the inclusion criteria in six hospitals in Sichuan Province, Sichuan Province, were selected from the first chemotherapy cycle using PEG-rhG-CSF (can be any chemotherapy cycle of the patient), and each subsequent chemotherapy cycle was recorded. The use of PEG-rhG-CSF and related patient outcomes until the end of chemotherapy. Analyze the clinical practice of using PEG-rhG-CSF in the real world.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 800
Inclusion Criteria
- Age ≥ 18 years old;
- Diagnosed as a malignant solid tumor by histology and cytology, requiring chemotherapy patients;
- The first use of PEG-rhG-CSF during the chemotherapy cycle (not limited to the first chemotherapy cycle, can be any chemotherapy cycle of the patient);
- Subjects volunteered to participate in this clinical trial and signed informed consent.
Exclusion Criteria
- PEG-rhG-CSF was used in the current chemotherapy cycle;
- Have received hematopoietic stem cell transplantation or bone marrow transplantation;
- Other drug clinical trials are currently underway.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dosage of PEG-rhG-CSF in chemotherapy 1 YEAR Administration time of PEG-rhG-CSF in chemotherapy 1 YEAR dosing frequency of PEG-rhG-CSF in chemotherapy 1 YEAR
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Affiliated Hospital of North Sichuan Medical College
🇨🇳Nanchong, Sichuan, China